Biocompatible Gold Nanorod Conjugates for Preclinical Biomedical Research

Gold nanorods with a peak absorption wavelength of 760 nm were prepared using a seed-mediated method. A novel protocol has been developed to replace hexadecyltrimethylammonium bromide on the surface of the nanorods with 16-mercaptohexadecanoic acid and metoxy-poly(ethylene glycol)-thiol, and the monoclonal antibody HER2. The physical chemistry properties of the conjugates were monitored through optical and zeta-potential measurements to confirm surface chemistry changes. The efficiency of the modifications was quantified through measurement of the average number of antibodies per gold nanorod. The conjugates were investigated for different cells lines: BT-474, MCF7, MCF10, MDCK, and fibroblast. The results show successful cell accumulation of the gold nanorod HER2 conjugates in cells with HER2 overexpression. Incubation of the complexes in heparinized mouse blood demonstrated the low aggregation of the metallic particles through stability of the spectral properties, as verified by UV/VIS spectrometry. Cytotoxicity analysis with LDH release and MTT assay confirms strong targeting and retention of functional activity of the antibody after their conjugation with gold nanorods. Silver staining confirms efficient specific binding to BT-474 cells even in cases where the nanorod complexes were incubated in heparinized mouse blood. This is confirmed through in vivo studies where, following intravenous injection of gold nanorod complexes, silver staining reveals noticeably higher rates of specific binding in mouse tumors than in healthy liver. The conjugates are reproducible, have strong molecular targeting capabilities, have long term stability in vivo and can be used in pre-clinical applications. The conjugates can also be used for molecular and optoacoustic imaging, quantitative sensing of biological substrates, and photothermal therapy

Laser nanothermolysis of human leukemia cells using functionalized plasmonic nanoparticles

In the present work, we present the use of gold nanorods as plasmonic nanoparticles for selective photothermal therapy of human acute (HL-60) and chronicle (K-562) leukemia cells using a near-infrared laser. We improved a published methodology of gold nanorods conjugation to generate high yields of narrow band gold nanorods with an optical absorption centered at 760 nm. The manufactured nanorods were pegylated and conjugated with monoclonal antibody to become non-toxic as biocompatible nanothermolysis agent. Gold nanorods are synthesized and conjugated to CD33 monoclonal antibody. After pegylation, or conjugation with CD33 antibody, gold nanorods were non-toxic to acute and chronic leukemia cells. Our modified gold nanorods CD33 conjugates shown high level of accumulation for both leukemia cell lines, and successful used for nanothermolysis of human leukemia cells in vitro. Each sample was illuminated with 1 or 3 laser shots as for low and for high laser fluence. The radiation was provided by a Quanta Systems q-switched titanium sapphire laser, and the system was designed for maximum sample coverage using non-focused illumination. HL-60 and K-562 cells were treated for 45 min with gold nanorods CD33 conjugated, or with pegylated gold nanorods. The effect of pulsed-laser nanothermolysis for acute and chronic leukemia cells were investigated with cell counting for number of living cells, percentage of cell death and functional parameters such as damage of cell membrane and metabolic activity. Gold nanorods CD33 conjugates significantly increase cell damage for low fluence laser and completely destroyed cancer cells after 3 pulses for low fluence (acute leukemia) and for high fluence laser as for HL-60 (acute) and for K-562 (chronicle) leukemia cells

Accelerating Gold Nanorod Synthesis with Nanomolar Concentrations of Poly(vinylpyrrolidone)

A novel modification for the seedless synthesis of gold nanorods (AuNRs) has been developed. Nanomolar concentrations of 10 kDa poly­(vinylpyrrolidone) (PVP) can be introduced to a growth solution containing 25, 50, or 100 mM cetyltrimethylammonium bromide (CTAB) to significantly reduce the dimensions of AuNRs. We found that PVP accelerates the growth rate of AuNRs by more than two times that of nanorods grown in 50 and 100 mM CTAB solutions. Additionally, there is a time-dependent effect of adding PVP to the nanorod growth solution that can be utilized to tune their aspect ratio. Because the concentration of PVP is far below the concentration of HAuCl₄ in the reaction mixture, PVP primarily functions not as a reducing agent, but as a capping or templating ligand to stabilize the growing nanorods. Our reproducible protocol enables the synthesis of AuNRs in high yield with tunable sizes: 45 × 6.7, 28 × 5.5, and 12 × 4.5 nm for 100, 50, and 25 mM CTAB, respectively. We estimated the number of PVP chains per nanorod in growth solutions to be around 30, which suggests that the effect on the aspect ratio is caused by a direct interaction between the AuNR surface and the PVP